We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Have you been diagnosed with eczema that is not responding to treatment? If so, you may be eligible to participate in a study to help researchers find out if an investigational drug called tradipitant is safe and effective at treating eczema. Eligible participants are 18-70 years old and have chronic itchy skin despite the use of steroids and antihistamines. Compensation provided.
IRB: SSU00073519
- Vanda Pharmaceuticals, Inc. – VP-VLY-686-3101, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY STUDY OF THE NEUROKININ-1 RECEPTOR ANTAGONIST VLY-686 IN PATIENTS WITH ATOPIC DETERMATITIS (Pro00025510)MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.